O-029 Tumor-targeted niosome as novel carrier for intravenous administration of tocotrienol  by Fu, Ju-Yen et al.
Original Research Paper
O-029
Tumor-targeted niosome as novel carrier for
intravenous administration of tocotrienol
Ju-Yen Fu a,*, Doryn MeamYee Tan a,b, Hui Meng Er b, Yu Sui Chen b,
Kalanithi Nesaretnam a
a Malaysian Palm Oil Board, Bandar Baru Bangi, Selangor 43000, Malaysia
b International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia
A R T I C L E I N F O
Article history:






Tocotrienol (T3), the unsaturated form of vitamin E, has gained
global attention due to its potent anticancer effects against a
wide range of cancers. Found abundantly in palm oil [1],T3 was
reported to exhibit their anti-cancer properties via various path-
ways including anti-proliferative, anti-angiogenesis, anti-
inflammatory, apoptosis and improvement of immunological
function [2]. However, the lack of tumor specificity and rapid
body clearance have restricted the clinical applications of T3
[3]. Nanotechnology offers an alternative approach to novel for-
mulation of tocotrienols as the sub-micron sized niosomes are
able to enhance both pharmacokinetic and surface proper-
ties of tocotrienol. In this study, transferrin will be investigated
as the targeting protein able to recognize the overexpressed
transferrin receptors on breast cancer cells. The main objec-
tives of this study are to develop a tumor-targeted nanocarrier-
based delivery system for intravenous injection of T3, and
evaluate the therapeutic efficacy in human breast cancer cells
and murine xenograft tumor models.
Using film hydration method, spherical niosomes with size
less than 200 nm were synthesized. The average encapsula-
tion efficiency, drug loading and transferrin- conjugation
efficiency were 28.0%, 5.8% and 13.1%, respectively. The en-
capsulation ofT3 in niosomes significantly improves the in vitro
performance of T3, with at least 2-fold enhancement in cyto-
toxicity effect and 2.5-fold increment in T3 uptake in human
breast cancer cells. In animal model, breast cancer cells were
subcutaneously implanted to female BALB/c nude mice.Treat-
ment with tumor-targeted niosomes encapsulated T3 showed
reduced tumor volume of 3 times smaller than those in-
jected with freeT3. Note worthily, no sign of adverse effect and
significant weight loss were observed in all treatment groups.
The results were summarized in Fig. 1.
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In current work, we demonstrated that the encapsulation
of T3 in tumor-targeted niosomes resulted in enhanced cyto-
toxicity andT3 uptake in human breast cancer cells.Meanwhile,
significant lower rate of tumor growth and tumor volume was
observed in tumor-bearing mice treated with tumor-targeted
niosomes encapsulating T3.This study exploits the therapeu-
tic potential of T3 cancer therapy for the widespread benefits
of patients suffering from cancers.
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Fig. 1 – Transmission electron micrograph of T3 in tumor targeted niosomes (A) and tumor volume at day 20 in mice
bearing breast cancer tumors treated with tumor-targeted T3 niosomes (green), non-targeted T3 niosomes (blue), free T3
(red) and untreated group (black). *Indicates significant difference between groups (p < 0.05).
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